Williams Laura A 4

4 · ARDELYX, INC. · Filed Jan 26, 2026

AI-generated summary of this filing

Updated Jan 26, 2026

ARDX Chief Patient Officer Laura Williams Receives Stock Awards

What Happened

Laura A. Williams, Chief Patient Officer of Ardelyx, received equity awards on January 23, 2026 totaling 206,735 shares (82,695 RSUs and 124,040 shares via a derivative award). Both awards were reported at $0.00 per share at grant (no cash paid at grant).

Key Details

Transaction date: January 23, 2026; filing date: January 26, 2026 (timely filing).
Awards: 82,695 restricted stock units (RSUs) and 124,040 shares via a derivative award (reported as an acquisition).
Price: $0.00 per share at grant (standard for restricted grants/options).
Shares potentially issuable in total: 206,735.
Shares owned after the transaction: Not specified in the provided filing excerpt.
Footnotes:
- F1: RSUs — each RSU converts to one share of common stock upon vesting.
- F2: The derivative is an option-like award that becomes exercisable as it vests; the shares vest in 48 equal monthly installments beginning January 23, 2026, subject to continued employment.
No indication of a 10b5-1 plan, cashless sale, gift, or tax-withholding sale in the provided excerpt.

Context

These are grants/awards (not open-market purchases or sales). Grants at $0 are common for employee compensation and reflect potential future share issuance as awards vest or options are exercised. The derivative award vests monthly over four years, meaning the economic exposure depends on continued service and future exercise/vesting events.

Form 4

Period: 2026-01-23

See Remarks

Transactions

Award
Common Stock
[F1]
2026-01-23+82,695→ 444,258 total
Award
Stock Option (Right to Buy)
[F2]
2026-01-23+124,040→ 124,040 total
Exercise: $7.77Exp: 2036-01-23→ Common Stock (124,040 underlying)

Footnotes (2)

[F1]Restricted stock units ("RSUs"). The Reporting Person is entitled to receive one (1) shares of Common Stock for each one (1) RSU upon the vesting thereof.
[F2]The option becomes exercisable as it vests and the shares subject to the option vest in 48 successive, equal monthly installments on each monthly anniversary of January 23, 2026, subject to the Reporting Person's continued employment or service relationship with the Issuer on each such vesting date.

Signature

/s/ Elizabeth Grammer, Attorney-in-Fact for Laura A. Williams|2026-01-26

1 file